StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

by · The Cerbat Gem

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research report report published on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

NASDAQ TRVN opened at $1.46 on Monday. The company has a market cap of $1.24 million, a P/E ratio of -0.54 and a beta of 1.02. The business’s 50 day moving average price is $4.33 and its 200-day moving average price is $7.15. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $19.23.

Trevena (NASDAQ:TRVN – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($9.25) by $9.02. The business had revenue of $0.33 million during the quarter. As a group, equities analysts predict that Trevena will post -32.25 EPS for the current year.

About Trevena

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Articles